UBS Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.74M | Sell |
12,600
-1,700
| -12% | -$1.3M | ﹤0.01% | 3380 |
|
|
2025
Q4 | $11M | Sell |
14,300
-7,900
| -36% | -$5.37M | ﹤0.01% | 3183 |
|
|
2025
Q3 | $12.5M | Hold |
22,200
| – | – | ﹤0.01% | 3053 |
|
|
2025
Q2 | $11.7M | Sell |
22,200
-36,500
| -62% | -$20.4M | ﹤0.01% | 2922 |
|
|
2025
Q1 | $37.2M | Sell |
58,700
-63,000
| -52% | -$43.3M | 0.01% | 1745 |
|
|
2024
Q4 | $86.7M | Buy |
121,700
+18,800
| +18% | +$15.8M | 0.02% | 1011 |
|
|
2024
Q3 | $108M | Buy |
102,900
+5,700
| +6% | +$6.34M | 0.02% | 682 |
|
|
2024
Q2 | $102M | Sell |
97,200
-19,800
| -17% | -$19.2M | 0.03% | 646 |
|
|
2024
Q1 | $113M | Sell |
117,000
-20,900
| -15% | -$19.9M | 0.03% | 595 |
|
|
2023
Q4 | $121M | Buy |
137,900
+12,100
| +10% | +$9.96M | 0.04% | 493 |
|
|
2023
Q3 | $104M | Buy |
125,800
+21,800
| +21% | +$17.1M | 0.04% | 491 |
|
|
2023
Q2 | $74.7M | Sell |
104,000
-15,300
| -13% | -$11.8M | 0.03% | 619 |
|
|
2023
Q1 | $98M | Sell |
119,300
-40,400
| -25% | -$30.5M | 0.04% | 464 |
|
|
2022
Q4 | $115M | Buy |
159,700
+1,200
| +0.8% | +$885K | 0.04% | 438 |
|
|
2022
Q3 | $109M | Sell |
158,500
-3,800
| -2% | -$2.39M | 0.05% | 403 |
|
|
2022
Q2 | $95.9M | Buy |
162,300
+13,800
| +9% | +$8.97M | 0.04% | 459 |
|
|
2022
Q1 | $104M | Buy |
148,500
+14,500
| +11% | +$9.17M | 0.03% | 514 |
|
|
2021
Q4 | $84.6M | Buy |
134,000
+51,387
| +62% | +$31.6M | 0.02% | 672 |
|
|
2021
Q3 | $50M | Buy |
82,613
+7,200
| +10% | +$4.47M | 0.02% | 868 |
|
|
2021
Q2 | $42.1M | Buy |
75,413
+5,800
| +8% | +$2.94M | 0.01% | 959 |
|
|
2021
Q1 | $32.9M | Buy |
+69,613
| New | +$33.9M | 0.01% | 1098 |
|
|
2019
Q2 | – | Sell |
-27,500
| Closed | -$11.3M | – | 8106 |
|
|
2019
Q1 | $11.3M | Sell |
27,500
-40,000
| -59% | -$16.5M | ﹤0.01% | 1582 |
|
|
2018
Q4 | $25.2M | Hold |
67,500
| – | – | 0.01% | 934 |
|
|
2018
Q3 | $27.3M | Buy |
67,500
+1,000
| +2% | +$381K | 0.01% | 1005 |
|
|
2018
Q2 | $22.9M | Buy |
66,500
+100
| +0.2% | +$31.3K | 0.01% | 1084 |
|
|
2018
Q1 | $22.9M | Buy |
66,400
+400
| +0.6% | +$139K | 0.01% | 1059 |
|
|
2017
Q4 | $24.8M | Buy |
66,000
+23,000
| +53% | +$9.31M | 0.01% | 1053 |
|
|
2017
Q3 | $19.2M | Sell |
43,000
-23,000
| -35% | -$10.9M | 0.01% | 1122 |
|
|
2017
Q2 | $32.4M | Buy |
66,000
+22,900
| +53% | +$10M | 0.02% | 775 |
|
|
2017
Q1 | $16.7M | Buy |
43,100
+7,900
| +22% | +$2.93M | 0.01% | 1142 |
|
|
2016
Q4 | $12.9M | Buy |
35,200
+10,100
| +40% | +$3.84M | 0.01% | 1311 |
|
|
2016
Q3 | $10.1M | Buy |
+25,100
| New | +$10.1M | 0.01% | 1402 |
|
|
2016
Q1 | – | Sell |
-1,800
| Closed | -$977K | – | 8066 |
|
|
2015
Q4 | $977K | Hold |
1,800
| – | – | ﹤0.01% | 3425 |
|
|
2015
Q3 | $837K | Hold |
1,800
| – | – | ﹤0.01% | 3517 |
|
|
2015
Q2 | $918K | Sell |
1,800
-400
| -18% | -$195K | ﹤0.01% | 3639 |
|
|
2015
Q1 | $993K | Sell |
2,200
-21,500
| -91% | -$9.11M | ﹤0.01% | 3588 |
|
|
2014
Q4 | $9.72M | Buy |
+23,700
| New | +$9.32M | 0.01% | 1526 |
|
Other funds holding REGN
VCM
N
UBS Group's REGN Position: Q1 2026 in Review
UBS Group increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $22.1M and bringing the position to 299,979 shares worth $232M. The position accounts for 0.03% of the portfolio, ranked #548.
UBS Group first reported a position in REGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $286M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- UBS Group held 299,979 shares of Regeneron Pharmaceuticals worth $232M as of Q1 2026.
- UBS Group bought 28,821 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $22.1M.
- Regeneron Pharmaceuticals made up 0.03% of UBS Group's portfolio in Q1 2026, its #548 holding.
- UBS Group first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Regeneron Pharmaceuticals position peaked at $286M in Q3 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.